Cellular, synaptic, and circuit effects of antibodies in autoimmune CNS synaptopathies

Handbook of Clinical Neurology

Volumn 133, Issue , 2016, Pages 77-93

  Jain, Ankit ^a   Balice Gordon, Rita ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PFIZER INC   (United States)

Author keywords

Anti NMDA receptor encephalitis; Autoimmune encephalitis; Autoimmune synaptopathy; Synaptic autoimmunity

Indexed keywords

4 AMINOBUTYRIC ACID; AUTOANTIBODY; MEMBRANE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL; HUMAN; IMMUNOLOGY; METABOLISM; NEUROLOGIC DISEASE; PATHOLOGY; SYNAPSE;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; GAMMA-AMINOBUTYRIC ACID; HUMANS; MEMBRANE PROTEINS; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES;

EID: 84978402413     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63432-0.00005-0     Document Type: Chapter

References (113)

1. Ances B.M., Vitaliani R., Taylor R.A., et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005, 128:1764-1777.
2. Armangue T., Titulaer M.J., Málaga I., et al. Pediatric anti-N-methyl-d-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013, 162:850-856. e2.
3. Belforte J.E., Zsiros V., Sklar E.R., et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010, 13:76-83.
4. Boillot M., Huneau C., Marsan E., et al. Glutamatergic neuron-targeted loss of LGI1 epilepsy gene results in seizures. Brain 2014, awu259.
5. Buckley C., Oger J., Clover L., et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001, 50:73-78.
6. Burrone J., O'Byrne M., Murthy V.N. Multiple forms of synaptic plasticity triggered by selective suppression of activity in individual neurons. Nature 2002, 420:414-418.
7. Coyle J.T., Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 2003, 59:491-515.
8. Dalmau J., Rosenfeld M.R. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008, 7:327-340.
9. Dalmau J., Tüzün E., Wu H., et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61:25-36.
10. Dalmau J., Gleichman A.J., Hughes E.G., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7:1091-1098.
11. Dalva M.B., Takasu M.A., Lin M.Z., et al. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 2000, 103:945-956.
12. Dalva M.B., McClelland A.C., Kayser M.S. Cell adhesion molecules: signalling functions at the synapse. Nat Rev Neurosci 2007, 8:206-220.
13. DeGiorgio L.A., Konstantinov K.N., Lee S.C., et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001, 7:1189-1193.
14. Drachman D.B., Angus C.W., Adams R.N., et al. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978, 298:1116-1122.
15. Engel A.G., Lambert E.H., Howard F.M. Immune complexes (IgG and C3) at the motor end plate in myasthenia gravis. Ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977, 52:267-280.
16. Epsztein J., Milh M., Bihi R.I., et al. Ongoing epileptiform activity in the post-ischemic hippocampus is associated with a permanent shift of the excitatory-inhibitory synaptic balance in CA3 pyramidal neurons. J Neurosci 2006, 26:7082-7092.
17. Esposito P., Chandler N., Kandere K., et al. Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002, 303:1061-1066.
18. Feldmeyer D., Kask K., Brusa R., et al. Neurological dysfunctions in mice expressing different levels of the Q/R site-unedited AMPAR subunit GluR-B. Nat Neurosci 1999, 2:57-64.
19. Finke C., Kopp U.A., Scheel M., et al. Functional and structural brain changes in anti-N-methyl-d-aspartate receptor encephalitis. Ann Neurol 2013, 74:284-296.
20. Florance N.R., Davis R.L., Lam C., et al. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009, 66:11-18.
21. Fukata Y., Lovero K.L., Iwanaga T., et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci U S A 2010, 107:3799-3804.
22. Gerlai R., Henderson J.T., Roder J.C., et al. Multiple behavioral anomalies in GluR2 mutant mice exhibiting enhanced LTP. Behav Brain Res 1998, 95:37-45.
23. Gresa-Arribas N., Titulaer M.J., Torrents A., et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014, 13:167-177.
24. Guyon T., Levasseur P., Truffault F., et al. Regulation of acetylcholine receptor α subunit variants in human myasthenia gravis: quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction. J Clin Invest 1994, 94:16-24.
25. Guyon T., Wakkach A., Poea S., et al. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. J Clin Invest 1998, 102:249-263.
26. Hauser S.L., Waubant E., Arnold D.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
27. Herin G.A., Aizenman E. Amino terminal domain regulation of NMDA receptor function. Eur J Pharmacol 2004, 500:101-111.
28. Höftberger R., Titulaer M.J., Sabater L., et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013, 81:1500-1506.
29. Huber J.D., Witt K.A., Hom S., et al. Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 2001, 280:H1241-H1248.
30. Huerta P.T., Kowal C., DeGiorgio L.A., et al. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A 2006, 103:678-683.
31. Hughes E.G., Peng X., Gleichman A.J., et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010, 30:5866-5875.
32. Irani S.R., Alexander S., Waters P., et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010, 133:2734-2748.
33. Irani S.R., Michell A.W., Lang B., et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011, 69:892-900.
34. Jahn K., Franke C., Bufler J. Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis. Neurology 2000, 54:474-479.
35. Jia Z., Agopyan N., Miu P., et al. Enhanced LTP in mice deficient in the AMPA receptor GluR2. Neuron 1996, 17:945-956.
36. Kapur S., Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors - Implications for models of schizophrenia. Mol Psychiatry 2002, 7:837-844.
37. Kehrer C., Maziashvili N., Dugladze T., et al. Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. Front Mol Neurosci 2008, 1:6.
38. Kendrick S.J., Lynch D.R., Pritchett D.B. Characterization of glutamate binding sites in receptors assembled from transfected NMDA receptor subunits. J Neurochem 1996, 67:608-616.
39. Kinoshita M., McDannold N., Jolesz F.A., et al. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun 2006, 340:1085-1090.
40. Klein C.J., Lennon V.A., Aston P.A., et al. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 2013, 70:229-234.
41. Krystal J.H. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry 2002, 59:663-664.
42. Krystal J.H., Karper L.P., Seibyl J.P., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
43. Labrie V., Lipina T., Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2008, 200:217-230.
44. Lahti A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25:455-467.
45. Lai M., Hughes E.G., Peng X., et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009, 65:424-434.
46. Lai M., Huijbers M.G.M., Lancaster E., et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010, 9:776-785.
47. Lancaster E., Lai M., Peng X., et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterization of the antigen. Lancet Neurol 2010, 9:67-76.
48. Lancaster E., Huijbers M.G.M., Bar V., et al. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011, 69:303-311.
49. Laube U., Kiderlen A.F. Detection of Pneumocystis carinii with DNA-binding bisBenzimide 33258 Hoechst. J Eukaryot Microbiol 1997, 44:35S.
50. Leypoldt F., Armangue T., Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci 2014, 1-21.
51. Li Y., Erzurumlu R.S., Chen C., et al. Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell 1994, 76:427-437.
52. Liguori R., Vincent A., Clover L., et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001, 124:2417-2426.
53. Lu W., Shi Y., Jackson A.C., et al. Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach. Neuron 2009, 62:254-268.
54. Luby E.D., Gottlieb J.S., Cohen B.D., et al. Model psychoses and schizophrenia. Am J Psychiatry 1962, 119:61-67.
55. Lucchinetti C.F., Mandler R.N., McGavern D., et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
56. Martinez-Hernandez E., Horvath J., Shiloh-Malawsky Y., et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011, 77:589-593.
57. Mikasova L., De Rossi P., Bouchet D., et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 2012, 135:1606-1621.
58. Mohn A.R., Gainetdinov R.R., Caron M.G., et al. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
59. Mombereau C., Kaupmann K., Froestl W., et al. Genetic and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 2004, 29:1050-1062.
60. Monyer H., Burnashev N., Laurie D.J., et al. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994, 12:529-540.
61. Moscato E.H., Jain A., Peng X., et al. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci 2010, 32:298-309.
62. Moscato E.H., Peng X., Jain A., et al. Acute mechanisms underlying antibody effects in anti-N-methyl-d-aspartate receptor encephalitis. Ann Neurol 2014, 76:108-119.
63. Nagel A., Engel A.G., Lang B., et al. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation. Ann Neurol 1988, 24:552-558.
64. Nakagawa Y., Sasaki A., Takashima T. The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats. Eur J Pharmacol 1999, 381:1-7.
65. Nakazawa K., McHugh T.J., Wilson M.A., et al. NMDA receptors, place cells and hippocampal spatial memory. Nat Rev Neurosci 2004, 5:361-372.
66. Neuwelt E.A., Barnett P.A., Hellstrom I., et al. Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 1988, 48:4725-4729.
67. Nobile C., Michelucci R., Andreazza S., et al. LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy. Hum Mutat 2009, 30:530-536.
68. Oguro K., Oguro N., Kojima T., et al. Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons. J Neurosci 1999, 19:9218-9227.
69. Ohkawa T., Fukata Y., Yamasaki M., et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013, 33:18161-18174.
70. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999, 33:523-533.
71. Palmer C.L., Cotton L., Henley J.M. The molecular pharmacology and cell biology of α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev 2005, 57:253-277.
72. Paoletti P., Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007, 7:39-47.
73. Peers C., Johnston I., Lang B., et al. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction. Neurosci Lett 1993, 153:45-48.
74. Peng X., Hughes E.G., Moscato E.H., et al. Cellular plasticity induced by anti-AMPA receptor encephalitis antibodies. Ann Neurol 2015, 77:381-398.
75. Petit-Pedrol M., Armangue T., Peng X., et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014, 13:276-286.
76. A receptor α1 and α2 subunits: clinical and serologic characterization. Neurology 2015, 84:122-1241.
77. Pinto A., Gillard S., Moss F., et al. Human autoantibodies specific for the α(1A) calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci U S A 1998, 95:8328-8333.
78. Planaguma J., Leypoldt F., Mannara F., et al. Human N-methyl-d-aspartate receptor antibodies alter memory and behavior in mice. Brain 2014, awu310.
79. Plomp J.J., Van Kempen G.T.H., De Baets M.B.H., et al. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol 1995, 37:627-636.
80. Prange O., Wong T.P., Gerrow K., et al. A balance between excitatory and inhibitory synapses is controlled by PSD-95 and neuroligin. Proc Natl Acad Sci U S A 2004, 101:13915-13920.
81. Prosser H.M., Gill C.H., Hirst W.D., et al. Epileptogenesis and enhanced prepulse inhibition in GABA(B1)-deficient mice. Mol Cell Neurosci 2001, 17:1059-1070.
82. Rabchevsky A.G., Degos J.-D., Dreyfus P.A. Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Res 1999, 832:84-96.
83. Rassendren F.-A., Lory P., Pin J.-P., et al. Zinc has opposite effects on NMDA and Non-NMDA receptors expressed in xenopus oocytes. Neuron 1990, 4:733-740.
84. Reisel D., Bannerman D.M., Schmitt W.B., et al. Spatial memory dissociations in mice lacking GluR1. Nat Neurosci 2002, 5:868-873.
85. Sahashi K., Engel A.G., Lambert E.H., et al. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980, 39:160-172.
86. Sanderson D.J., Gray A., Simon A., et al. Deletion of glutamate receptor-A (GluR-A) AMPA receptor subunits impairs one-trial spatial memory. Behav Neurosci 2007, 121:559-569.
87. Sansing L.H., Tüzün E., Ko M.W., et al. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007, 3:291-296.
88. Schmitt A., Fendt M., Zink M., et al. Altered NMDA receptor expression and behavior following postnatal hypoxia: potential relevance to schizophrenia. J Neural Transm 2007, 114:239-248.
89. Schmitt S.E., Pargeon K., Frechette E.S., et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012, 79:1094-1100.
90. Schulte U., Thumfart J.-O., Klöcker N., et al. The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvbeta1. Neuron 2006, 49:697-706.
91. Shepherd J.D., Huganir R.L. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol 2007, 23:613-643.
92. + channels of peripheral nerves. Ann Neurol 1995, 38:714-722.
93. 18FDG-PET in anti-AMPA receptor limbic encephalitis. J Neuroimmunol 2014, 271:53-55.
94. Sprengel R. Role of AMPA receptors in synaptic plasticity. Cell Tissue Res 2006, 326:447-455.
95. Stahl S.M. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr 2007, 12:265-268.
96. Standaert D.G., Testa C.M., Young A.B., et al. Organization of N-methyl-d-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol 1994, 343:1-16.
97. Stein-Wexler R., Wootton-Gorges S.L., Greco C.M., et al. Paraneoplastic limbic encephalitis in a teenage girl with an immature ovarian teratoma. Pediatr Radiol 2005, 35:694-697.
98. Sutton M.A., Ito H.T., Cressy P., et al. Miniature neurotransmission stabilizes synaptic function via tonic suppression of local dendritic protein synthesis. Cell 2006, 125:785-799.
99. Teng Y., Xie X., Walker S., et al. Knockdown of zebrafish Lgi1a results in abnormal development, brain defects and a seizure-like behavioral phenotype. Hum Mol Genet 2010, 19:4409-4420.
100. Thieben M.J., Lennon V.A., Boeve B.F., et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004, 62:1177-1182.
101. Tsien J.Z., Huerta P.T., Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 1996, 87:1327-1338.
102. Turrigiano G.G., Leslie K.R., Desai N.S., et al. Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature 1998, 391:892-896.
103. Vitaliani R., Mason W., Ances B., et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005, 58:594-604.
104. Waters P., Jarius S., Littleton E., et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008, 65:913-919.
105. Waxman E.A., Lynch D.R. N-methyl-d-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11:37-49.
106. Whitney K.D., Andrews P.I., McNamara J.O. Immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen's encephalitis. Neurology 1999, 53:699-708.
107. Wiedholz L.M., Owens W.A., Horton R.E., et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and "schizophrenia-related" behaviors. Mol Psychiatry 2008, 13:631-640.
108. Wilson S., Vincent A., Newsom Davis J. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis. J Neurol Neurosurg Psychiatry 1983, 46:383-387.
109. Xiao S., Jan L.Y. A gate keeper for axonal transport. Cell 2009, 136:996-998.
110. Yu Y.E., Wen L., Silva J., et al. Lgi1 null mutant mice exhibit myoclonic seizures and CA1 neuronal hyperexcitability. Hum Mol Genet 2010, 19:1702-1711.
111. Zamanillo D. Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science 1999, 284(80):1805-1811.
112. Zavitsanou K., Nguyen V., Newell K., et al. Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia. J Chem Neuroanat 2008, 36:71-76.
113. Zhang Q., Tanaka K., Sun P., et al. Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. Neurobiol Dis 2012, 45:610-615.